Recently, the Huada Institute of Life Sciences, in collaboration with multiple institutions, released a self-developed DNA synthesis technology based on parallel principles - mMPS technology. This technology, based on the innovative paradigm of microchips, has fundamentally disrupted DNA synthesis technology, achieving systematic breakthroughs in synthesis flux, yield, and quality. It is expected to provide key support for genome writing, rapid vaccine development, and DNA data storage. The relevant results were published in the international journal Nature Biotechnology. Overcoming the challenges of DNA synthesis quality and efficiency in the field of synthetic biology, DNA synthesis technology has always been regarded as a key bottleneck in breaking through industry development. Traditional high-throughput DNA synthesis technology involves synthesizing millions of short DNA fragments on a single chip surface. Although this technology can synthesize a large number of fragments at once, the yield of each fragment is extremely low, and cross contamination between fragments is prone to occur, seriously affecting the success rate of subsequent assembly of long fragments. Due to the inability of traditional technologies to simultaneously meet the demands of high throughput, long fragments, and low cost, it directly limits the in-depth development of cutting-edge research in complex metabolic pathways, chromosome engineering, and large-scale mutation library construction. Unlike traditional technology, mMPS technology adopts an innovative synthesis path: dividing a chip into independent, millimeter sized microchips, synthesizing only one short DNA strand on each microchip, and each chip surface has a unique identification code that can identify and sort DNA fragments, and track the entire synthesis process of the fragment. In addition, this technology endows the chip with the ability to be reused through a cycle mechanism of "recognition sorting synthesis recycling", laying a solid foundation for sustainable and low-cost DNA synthesis. Simply put, these microchips are like "workers" with dedicated job numbers. In the synthesis process, after the intelligent scanner recognizes the job number, it can quickly determine which specific short DNA strand each "worker" should synthesize. Then, different "workers" are accurately transported to the corresponding job position, namely the reaction column, through a conveyor belt, where a short DNA strand is synthesized. After the synthesis work is completed, these 'workers' can still be collected and put into the next round of work. Through this working mode, mMPS technology has achieved multiple breakthroughs in terms of increased output, simplified processes, and precise controllability. In terms of yield increase, the yield of a single DNA sequence has increased by 4-6 orders of magnitude; In terms of process simplification, the assembly of genes has been optimized from at least 5 steps to only 2 steps, without the need for additional amplification primers or enzyme cleavage sites, to avoid error accumulation; In terms of precision and controllability, each DNA fragment is synthesized in its own dedicated space, avoiding cross contamination, and the reaction conditions can be independently optimized according to demand. The research team has verified the excellent comprehensive performance of mMPS technology in multiple scenarios such as gene assembly and mutation library construction through systematic experiments. The research results fully demonstrate the unique advantages of this technology in processing complex sequences, high GC content regions, and repetitive sequences, providing reliable technical support for protein stability research and disease mutation mechanism analysis. It will help researchers explore key issues in the field of life sciences more deeply and lay the foundation for breakthroughs in disease treatment, new drug development, and other fields. At present, a standardized high-throughput synthesis platform based on mMPS technology has been incubated and implemented in Changzhou City, Jiangsu Province, demonstrating enormous application potential in multiple industries. This technology is expected to drive a systemic efficiency revolution in DNA synthesis across multiple fields. In the field of innovative drug development, identifying and optimizing key drug targets is an extremely important step. And behind this lies the construction of a high-quality mutant library. Compared to traditional methods that require several weeks to complete mutant library construction, mMPS technology can shorten this time to a few days, greatly accelerating antibody discovery and process optimization, and bringing "life-saving drugs" to patients earlier. In the field of biomanufacturing such as enzyme preparations, biobased materials, and fine chemicals, bacterial strains are the key factors determining industrial production efficiency and product performance. MMPS technology supports rapid enzyme directed evolution, which can shorten the strain modification cycle from several months to several weeks. Research has shown that the cost of single base synthesis is reduced by about 70% compared to traditional methods, paving the way for large-scale industrial applications. Biological manufacturing enterprises can use this to build exclusive enzyme libraries and metabolic pathway libraries. It is worth mentioning that the modular and automated features of mMPS technology provide a technical foundation for the rise of bio foundries. In the future, a new platform for DNA synthesis may emerge, providing the industry with a one-stop solution from DNA sequence design to functional verification through AI driven design, automated synthesis, and robot testing. With the maturity of reusable chip technology and further optimization of synthesis processes, mMPS technology will become the core engine of the next generation of industrial grade DNA synthesis factories. Shen Yue, Chief Scientist of Synthetic Biology at Huada Institute of Life Sciences, said, "The emergence of mMPS technology is not only an iteration in the field of DNA synthesis, but also a key turning point for synthetic biology from laboratory exploration to industrial manufacturing. In the future, with the promotion and application of mMPS technology, the design, construction, and testing of more complex biological systems will become possible, and synthetic biology is expected to usher in a true industrial explosion in fields such as medicine, energy, and environmental protection. ”Yuan Yingjin, an academician of the CAS Member, said: "mMPS technology not only demonstrates China's innovation ability in the field of basic tools of synthetic biology, but also lays an important foundation for building an independent and controllable biotechnology system, with significant academic value and industrialization prospects. ”(New Society)